參考文獻 |
Barnes, P., Pocock, S., Magnussen, H., Iqbal, A., Kramer, B., Higgins, M., & Lawrence, D. (2010). Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics,23,165–171.
Bauer, P., & Kieser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine, 18, 1833-1848.
Bauer, P., & Kohne, K. (1994). Evaluation of Experiments with Adaptive Interim Analyses. Biometrics, 50, 1029-1041.
Bretz, F., Schmidli, H., König, F., Racine, A., & Maurer, W. (2006). Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts. Biometrical Journal, 48, 623-634.
Chataway, J., Nicholas, R., Todd, S., Miller, D., Parsons, N., Valdés-Márquez, E., Stallard, N., &Friede, T. (2011). A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Multiple Sclerosis Journal,17,81–88.
Chow, S.-C., & Chang, M. (2008). Adaptive design methods in clinical trials – a review. Orphanet Journal of Rare Diseases, 3, 3-11.
Cook, R., & Farewell, V. (1996). Incorporating surrogate endpoints into group sequential trials.Biometrical Journal , 38, 119–130.
Dragalin, V. (2011). An introduction to adaptive designs and adaptation in CNS trials. European Neuropsychopharmacology, 21,153–158.
FDA. (1997). E8 General Considerations for Clinical Trials
FDA. (2019). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.
Friede, T., & Kieser, M. (2004). Sample size recalculation for binary data in internal pilot study designs. Pharmaceutical Statistics, 3, 269-279.
Friede, T., Parsons, N., & Stallard, N. (2012).A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine , 31, 4309–4320.
Friede, T., Parsons, N., Stallard, N., Todd, S., Valdés-Márquez, E., Chataway, J., & Nicholas, R. (2011). Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine, 30, 1528–1540.
Galbraith, S., & Marschner, I. (2003). Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. Statistics in Medicine ,22,1787–1805.
Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2006). Adaptive Designs in Clinical Drug Development-An Executive Summary of the PhRMA Working Group. Journal of Biopharmaceutical Statistics, 16, 275-283.
Ho, T. W., Pearlman, E., Lewis, D., Hämäläinen, M., Connor, K., Michelson, D, Zhang, Y., Assaid, C., Mozley, L. H., Strickler N. Bachman R., Mahoney, E., Lines, C., & Hewtt D. J. (2012). Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia, 32, 750-765.
Jenkins,M., Stone, A., & Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics ,10, 347-356.
Jennison, C., & Turnbull, B. W. (1999). Group Sequential Methods with Applications to Clinical Trials. CRC Press
Jennison, C., & Turnbull, B. W. (2005). Meta-Analyses and Adaptive Group Sequential Designs in the Clinical Development Process. Journal of Biopharmaceutical Statistics, 15, 537-558.
Kelly, P. J., Stallard, N., & Todd, S. (2005). An Adaptive Group Sequential Design for Phase II/III Clinical Trials that Select a Single Treatment From Several. Journal of Biopharmaceutical Statistics, 15, 641-658.
Kunz, C.U., Friede, T., Parsons, N., Todd, S., & Stallard, N. (2014). Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data. Pharmaceutical Statistics ,13, 238–246.
Kunz, C.U., Friede, T., Parsons, N., Todd, S., & Stallard, N. (2015). A comparison of methods for treatment selection in seamless phase II /III clinical trials incorporating information on short-term endpoints. Journal of Biopharmaceutical Statistics ,25, 170–189.
Lan, K. K. G., & Demets, D. L. (1989). Group sequential procedures: Calendar versus information time. Statistics in Medicine, 8, 1191-1198.
Liu, Q., & Chi, G. Y. H. (2001). On sample size and inference for two-stage adaptive designs. Biometrics, 57, 172-177.
Liu, Q., & Pledger, G. W. (2005). Phase 2 and 3 combination designs to accelerate drug development. Journal of the American Statistical Association ,100,493–502.
Maca, J., Bhattacharya, S., Dragalin, V., Gallo, P., & Krams, M. (2006). Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples. Drug Information Journal, 40, 463-473.
Magnusson, B. P., & Turnbull, B. W. (2013). Group sequential enrichment design incorporating subgroup selection. Statistics in Medicine, 32, 2695-2714.
Marschner, I., & Becker, S. (2001). Interim monitoring of clinical trials based on long-term binary endpoints. Statistics in Medicine ,20,177–192.
Nguyen Duc, A., Heinzmann, D., Berge, C., & Wolbers, M. (2021). A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies. Pharmaceutical Statistics,20,202– 211.
O′BRIEN, P. C., & FLEMING, T. R. (1979). A multiple testing procedure for clinical trials. Biometrics ,35, 549-56.
Ondra, T., Jobjörnsson, S., Beckman, R. A., Burman, C.-F., König, F., Stallard, N., & Posch, M. (2017). Optimized adaptive enrichment designs. Statistical Methods in Medical Research, 0, 1-16.
POCOCK, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika ,64,191-9.
Posch, M., & Bauer, P. (1999). Adaptive two-satge designs and the conditional error function. Biometrical Journal, 41, 689-696.
Proschan, M. A., & Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics, 51, 1315-1324.
Rosenberger, W. F., Stallard, N., Ivanova, A., Harper, C. N., & Ricks, M. L. (2001). Optimal adaptive designs for binary response trials. Biometrics, 57, 909-913.
Schmidli, H., Bretz, F., Racine, A., & Maurer, W. (2006). Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Applications and Practical Considerations. Biometrical Journal, 48, 635-643.
Schmoll, H., Cunnighmam, D., A., S., Krapetis, C., Rougier, P., Koski, S., P., B., Mookerjee,
B., Robertson, J., & van Cutsem, E. (2010). mFOLFOX6 + cediranib vs mFOLFOX6 +
bevacizumab in previously untreated metastatic colorectal cancer (mcrc): A randomised,
double-blind, phase II/III study (HORIZON III). Annals of Oncology ,21, vii189–vii224.
Shih, W. J. (2006). Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: a comparison. Statistics in Medicine, 25, 933-941.
Shun, Z., Lan, K.G., & Soo, Y., (2008). Interim treatment selection using the normal approximation approach in clinical trials. Stat Med,27, 597-618.
Simon R. (1989). Optimal two-stage designs for phase II clinical trials. Control Clin Trials, 10, 1-10.
Sooriyarachchi, M., Whitehead, J., Whitehead, A., & Bolland, K. (2006). The sequential analysis of repeated binary responses: A score test for the case of three time points. Statistics in Medicine, 25, 2196–2214.
Stallard N. (2010). A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Statistics in Medicine ,29, 959-971.
Stallard, N., & Todd, S.(2003). Sequential designs for phase III clinical trials incoporating treatment selection. Statistics in Medicine ,22, 689–703.
Stallard, N., Kunz, C.U., Todd, S., Parsons, N., & Friede, T. (2015). Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial. Statistics in Medicine ,34,3104–3115.
Thall, P. F., Simon, R., & Ellenberg, S. S. (1988). Two-Stage Selection and Testing Designs for Comparative Clinical Trials. Biometrika ,75, 303–310.
Todd, S., & Stallard, N. (2005). A new clinical trial design combining phases II and III: Sequential designs with treatment selection and a change of endpoint. Drug Information Journal ,39,109–118.
Wang, S.-J., James Hung, H. M., & O’Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal, 51, 358-374.
Wang, S. K., & Tsiatis, A. A. (1987). Approximately Optimal One-Parameter Boundaries for Group Sequential Trials. Biometrics, 43, 193-199.
Whitehead, A., Sooriyarachchi, M., Whitehead, J., & Bolland, K. (2008). Incorporating intermediate binary responses into interim analyses of clinical trials: A comparison of four methods. Statistics in Medicine ,27,1646–1666.
Whitehead, J. (1986). On the bias of maximum likelihood estimation following a sequentialtest. Biometrika ,73, 573-81.
吳緯綸(2021)。兩階段適應性無縫設計改良-於劑量選擇後加入一新試驗組之調整。國立中央大學統計研究所碩士論文。 |